Log In
Print
BCIQ
Print
Print this Print this
 

U300

  Manage Alerts
Collapse Summary General Information
Company Sanofi
Description300 units/mL formulation of insulin glargine, a synthetic sustained-release subcutaneous insulin analog
Molecular Target Insulin receptor (INSR)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type I diabetes; Treat Type II diabetes
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today